Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)
Japan · Delayed Price · Currency is JPY 6,044.00
-1.00 (-0.02%)
Apr 17, 2026, 3:30 PM JST
TYO:4530 Income Statement
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 |
| 163,024 | 156,006 | 141,706 | 128,330 | 120,193 | |
Revenue Growth (YoY) | 4.50% | 10.09% | 10.42% | 6.77% | 4.96% |
Cost of Revenue | 66,903 | 64,810 | 62,735 | 55,630 | 50,126 |
Gross Profit | 96,121 | 91,196 | 78,971 | 72,700 | 70,067 |
Selling, General & Admin | 78,203 | 61,312 | 57,157 | 51,282 | 50,125 |
Research & Development | - | 10,903 | 8,614 | 9,785 | 10,613 |
Operating Expenses | 78,203 | 72,300 | 65,803 | 61,099 | 60,730 |
Operating Income | 17,918 | 18,896 | 13,168 | 11,601 | 9,337 |
Interest Expense | -21 | -23 | -18 | -15 | -20 |
Interest & Investment Income | 3,642 | 3,993 | 3,684 | 1,872 | 1,058 |
Earnings From Equity Investments | 728 | 590 | 585 | 424 | 569 |
Currency Exchange Gain (Loss) | 935 | -176 | 1,778 | 1,973 | 1,276 |
Other Non Operating Income (Expenses) | 749 | 729 | 450 | 195 | 417 |
EBT Excluding Unusual Items | 23,951 | 24,009 | 19,647 | 16,050 | 12,637 |
Gain (Loss) on Sale of Investments | 137 | 5,019 | 389 | -257 | 653 |
Gain (Loss) on Sale of Assets | -63 | 1 | -6 | 320 | -55 |
Asset Writedown | - | -343 | -847 | - | - |
Other Unusual Items | -370 | - | 1 | -1 | -280 |
Pretax Income | 23,655 | 28,686 | 19,184 | 16,112 | 12,955 |
Income Tax Expense | 4,104 | 6,385 | 4,754 | 3,987 | 3,093 |
Earnings From Continuing Operations | 19,551 | 22,301 | 14,430 | 12,125 | 9,862 |
Minority Interest in Earnings | -391 | -543 | -461 | -383 | -204 |
Net Income | 19,160 | 21,758 | 13,969 | 11,742 | 9,658 |
Net Income to Common | 19,160 | 21,758 | 13,969 | 11,742 | 9,658 |
Net Income Growth | -11.94% | 55.76% | 18.97% | 21.58% | 4.41% |
Shares Outstanding (Basic) | 71 | 74 | 77 | 79 | 81 |
Shares Outstanding (Diluted) | 71 | 74 | 77 | 79 | 81 |
Shares Change (YoY) | -3.10% | -4.27% | -3.03% | -2.29% | -0.63% |
EPS (Basic) | 268.55 | 295.58 | 181.61 | 148.00 | 118.92 |
EPS (Diluted) | 268.22 | 295.15 | 181.42 | 147.88 | 118.84 |
EPS Growth | -9.12% | 62.69% | 22.68% | 24.44% | 5.07% |
Free Cash Flow | 9,483 | 5,138 | 5,264 | 4,868 | 15,589 |
Free Cash Flow Per Share | 132.75 | 69.70 | 68.36 | 61.30 | 191.82 |
Dividend Per Share | 45.000 | 86.000 | 85.000 | 84.000 | 84.000 |
Dividend Growth | -47.67% | 1.18% | 1.19% | - | 0.60% |
Gross Margin | 58.96% | 58.46% | 55.73% | 56.65% | 58.29% |
Operating Margin | 10.99% | 12.11% | 9.29% | 9.04% | 7.77% |
Profit Margin | 11.75% | 13.95% | 9.86% | 9.15% | 8.04% |
Free Cash Flow Margin | 5.82% | 3.29% | 3.72% | 3.79% | 12.97% |
EBITDA | 24,969 | 25,231 | 18,340 | 16,553 | 13,658 |
EBITDA Margin | 15.32% | 16.17% | 12.94% | 12.90% | 11.36% |
D&A For EBITDA | 7,051 | 6,335 | 5,172 | 4,952 | 4,321 |
EBIT | 17,918 | 18,896 | 13,168 | 11,601 | 9,337 |
EBIT Margin | 10.99% | 12.11% | 9.29% | 9.04% | 7.77% |
Effective Tax Rate | 17.35% | 22.26% | 24.78% | 24.75% | 23.88% |
Advertising Expenses | - | 29,953 | 28,214 | 23,549 | 25,406 |
Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.